Form 4: SpringWorks Therapeutics Director Receives Stock Grant
SEC Form 4
Director Carlos Alban received a grant of 10,060 restricted stock units (RSUs) from SpringWorks Therapeutics on May 14, 2025.
Summary
- Carlos Alban, a director of SpringWorks Therapeutics, received 10,060 restricted stock units (RSUs) on May 14, 2025.
- The RSUs were granted under the company's Amended and Restated Non-Employee Director Compensation Policy.
- These RSUs will vest fully on the earlier of May 14, 2026, or the date of the next annual meeting of stockholders, contingent upon continued service to the Issuer by the Reporting Person.
- Following the transaction, Mr. Alban beneficially owns 28,861 shares of common stock.
Sentiment
Score: 7
Explanation: The document reflects a standard compensation practice, suggesting stability and alignment of interests. The sentiment is neutral to slightly positive.
Positives
- The grant of RSUs aligns the director's interests with those of the shareholders.
- The vesting schedule incentivizes continued service to the company.
Future Outlook
The document outlines the terms of an equity grant, indicating a continued commitment to compensating non-employee directors with equity-based awards.
Industry Context
Equity grants to directors are a common practice in the pharmaceutical industry to align their interests with those of shareholders and incentivize long-term value creation.
Comparison to Industry Standards
- Director compensation packages, including equity grants, vary significantly across the pharmaceutical industry depending on company size, performance, and board responsibilities.
- Comparing SpringWorks' director compensation to peers like Deciphera Pharmaceuticals or Blueprint Medicines could provide a benchmark for assessing the competitiveness of their equity grants.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Policy | The grant was made pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy. | 05/14/2025 | The policy provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. |
Stakeholder Impact
- Shareholders may view the equity grant positively as it aligns director interests with long-term company performance.
- The director benefits from the equity grant, incentivizing continued service and contribution to the company.
Key Dates
| Date | Description |
|---|---|
| 05/14/2025 | Date of RSU grant to Carlos Alban |
| 05/15/2025 | Date of signature on the Form 4 filing |
| 05/14/2026 | First possible vesting date for the RSUs |
Keywords
SpringWorks Therapeutics, Director Compensation, Restricted Stock Units, RSUs, Equity Grant, Carlos Alban, SWTX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.